lnu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Hur effektiv och säker är kombinationen av sofosbuvir och velpatasvir mot kronisk hepatit C-infektion
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences.
2017 (Swedish)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

Around 130-150 million people are chronically infected with hepatitis C-virus today. Personal suffering and great societal costs aside, this also causes around 400 000 deaths every year due to complications.

Earlier treatments with pegylated interferon and ribavirin were both ineffective and had a lot of side effects, but in recent years new treatments using direct-acting antivirals that are both more effective and has less side effects have been introduced. The downside with these are that their effectiveness depends on which HCV genotype the patient has, which requires costly and time consuming pre-treatment examinations before treatment can begin.

This paper investigates clinical studies in which the effectiveness and side effects of a new combination of drugs containing sofosbuvir and velpatasvir is tested. The studies where found through PubMed, and they are what the usage of these drugs in health care is based on.

The studies show that the combination of sofosbuvir and velpatasvir is effective, measured by sustained virological response, against all HCV genotypes irrespective of if the patient has a compensated or decompensated cirrhosis, or if the patient has had a previously failed treatment. The patients with decompensated cirrhosis also had an early improvement in liver function, but it is too early to say if the improvement is long lasting. The treatment also gave less side effects compared to pegylated interferon and ribavirin. The combination of sofosbuvir and velpatasvir was also shown to have a good effect amongst patients where resistance associated variants of NS5A and NS5B where found.

The conclusion is that the combination of sofosbuvir and velpatasvir is an effective, but also at the moment expensive, treatment for HCV independent of genotype. 

Place, publisher, year, edition, pages
2017. , p. 40
Keywords [sv]
Hepatit C, sofosbuvir, velpatasvir
National Category
Biomedical Laboratory Science/Technology
Identifiers
URN: urn:nbn:se:lnu:diva-64721OAI: oai:DiVA.org:lnu-64721DiVA, id: diva2:1105251
Subject / course
Pharmacy
Educational program
Bachelor of Science Programme in Pharmacy, 180 credits
Supervisors
Examiners
Available from: 2017-06-08 Created: 2017-06-02 Last updated: 2017-06-08Bibliographically approved

Open Access in DiVA

fulltext(2088 kB)63 downloads
File information
File name FULLTEXT01.pdfFile size 2088 kBChecksum SHA-512
d0c0459db73f2bd7a51d86df9d841fa225635e2bfab8bb8bca15bf535a16a17b9c823db436ef58a306f41a4b898134b11d51a1a1b75163e26e2ddc6756a9a3f0
Type fulltextMimetype application/pdf

Search in DiVA

By author/editor
Rydén, Björn
By organisation
Department of Chemistry and Biomedical Sciences
Biomedical Laboratory Science/Technology

Search outside of DiVA

GoogleGoogle Scholar
Total: 63 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 121 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf